Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 8/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1927948 | 0.82 | HPGD (0.56) | ALDH1A1MAPTHPGDL3MBTL3L3MBTL1 | |
| SCHEMBL4050708 | 0.80 | HPGD (0.46) | ALDH1A1MAPTMGLLHPGDL3MBTL3 | |
| SCHEMBL28020408 | 0.80 | HPGD (0.59) | ALDH1A1MAPTKDM4EHPGDL3MBTL3 | |
| SCHEMBL2644377 | 0.78 | HPGD (0.67) | ALDH1A1MAPTMGLLHPGDL3MBTL3 | |
| SCHEMBL4053730 | 0.77 | HPGD (0.68) | ALDH1A1MAPTMGLLHPGD | |
| SCHEMBL4053727 | 0.77 | HPGD (0.68) | ALDH1A1MAPTMGLLHPGD | |
| SCHEMBL30957287 | 0.77 | HPGD (0.68) | ALDH1A1MAPTMGLLHPGD | |
| SCHEMBL1525473 | 0.76 | HPGD (0.53) | ALDH1A1MAPTHPGDL3MBTL3L3MBTL1 | |
| SCHEMBL15605882 | 0.75 | SMN1; SMN2 (0.65) | ALDH1A1MAPTMGLLHPGD | |
| SCHEMBL3459381 | 0.74 | FAAH (0.55) | ALDH1A1MAPTMGLLKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507753-B2 | melanocortin receptor agonist, antagonist; preventing or treating inflammatory diseases, AIDS, obesity, bulimia, anorexia or sexual dysfunction; N-(2-aminoethyl)-3'-[1-{N-(1-benzylpiperidin-4-yl)-N-(2-naphthylacetyl)aminoethyl][1,1'-biphenyl)-2-carboxamide dihydrochloride | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2009-03-24 | — | — | US | disclosed |
| US-20050096359-A1 | melanocortin receptor agonist, antagonist; preventing or treating inflammatory diseases, AIDS, obesity, bulimia, anorexia or sexual dysfunction; N-(2-aminoethyl)-3'-[1-{N-(1-benzylpiperidin-4-yl)-N-(2-naphthylacetyl)aminoethyl][1,1'-biphenyl)-2-carboxamide dihydrochloride | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-05 | — | — | US | disclosed |
| EP-1466904-A1 | BIARYL COMPOUND AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096359-A1 | melanocortin receptor agonist, antagonist; preventing or treating inflammatory diseases, AIDS, obesity, bulimia, anorexia or sexual dysfunction; N-(2-aminoethyl)-3'-[1-{N-(1-benzylpiperidin-4-yl)-N-(2-naphthylacetyl)aminoethyl][1,1'-biphenyl)-2-carboxamide dihydrochloride | MC4R, MC3R, MC1R | ALDH1A1 3865/4885MAPT 3995/4885MGLL 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.